北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第一临床医学院  > 风湿免疫科  > 期刊论文
学科主题: 临床医学
题名:
Efficacy, safety and tolerability of bosentan in Chinese patients with pulmonary arterial hypertension
作者: Jing, Zhi-Cheng1; Strange, Geoff2; Zhu, Xian-Yang3; Zhou, Da-Xin4; Shen, Jie-Yan5; Gu, Hong6; Yang, Zhen-Kun7; Pan, Xin8; Xiang, Mei-Xiang9; Yao, Hua10; Zhao, Dong-Bao11; Dalton, Brad S.12; Zhang, Zhuo-Li13; Wang, Yong14; Cheng, Xian-Sheng15; Yang, Yue-Jin15
关键词: pulmonary arterial hypertension ; bosentan
刊名: JOURNAL OF HEART AND LUNG TRANSPLANTATION
发表日期: 2010-02-01
DOI: 10.1016/j.healun.2009.09.020
卷: 29, 期:2, 页:150-156
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Cardiac & Cardiovascular Systems ; Respiratory System ; Surgery ; Transplantation
研究领域[WOS]: Cardiovascular System & Cardiology ; Respiratory System ; Surgery ; Transplantation
关键词[WOS]: CONGENITAL HEART-DISEASE ; RECEPTOR ANTAGONIST BOSENTAN ; EISENMENGER-SYNDROME ; EXERCISE CAPACITY ; 1ST-LINE BOSENTAN ; THERAPY ; SURVIVAL ; REGISTRY ; ADULTS ; MANAGEMENT
英文摘要:

BACKGROUND: Bosentan has an established role in the management of pulmonary arterial hypertension (PAH). This clinical trial assessed the benefits of bosentan in the Chinese population.

METHODS: We investigated the efficacy and safety of bosentan in 92 Chinese citizens (mean +/- standard deviation age, 29.0 +/- 3.8 years) with PAH for a minimum of 12 weeks. All received bosentan (62.5 mg twice daily) for 4 weeks; then, patients who weighed <40 kg received 62.5 mg bosentan twice daily and patients who weighed >40 kg received 125 mg twice daily. All patients were eligible to continue bosentan beyond 12 weeks. The primary end point was a chance in exercise capacity from baseline to 12 and 24 weeks. Secondary end points included a change in World Health Organization (WHO) functional class and changes in cardiopulmonary hemodynamics.

RESULTS: At baseline, 66 patients (72%) were in WHO functional class III; presentation was 37 (40%) with idiopathic PAH (iPAH), 34 (37%) with PAH related to congenital heart disease (CHD), and 21 (23%) with PAH related to connective tissue disease (CTD). Exercise capacity increased to 67.8 m after 12 weeks and 92.6 m after 24 weeks (p < 0.001). After 24 weeks, WHO functional class decreased (-0.8 +/- 0.6; p < 0.001), mean pulmonary artery pressure and pulmonary vascular resistance decreased (p < 0.01), ana cardiac output increased (p < 0.001). Twelve patients (13%) experienced at least 1 adverse event.

CONCLUSIONS: Bosentan improved exercise capacity, functional class, and cardiopulmonary hemodynamics in this patient cohort and was well tolerated. J Heart Lung Transplant 2010;29:150-6 (C) 2010 International Society for Heart and Lung Transplantation. All rights reserved.

语种: 英语
项目资助者: Actelion Pharmaceuticals
WOS记录号: WOS:000274755700002
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/56695
Appears in Collections:北京大学第一临床医学院_风湿免疫科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Guangzhou Gen Hosp, Dept Cardiol, Guangzhou, Guangdong, Peoples R China
2.Beijing Shijitan Hosp, Dept Pulm Vasc Dis, Beijing, Peoples R China
3.Monash Univ, Clayton, Vic 3800, Australia
4.Ruijin Hosp, Dept Cardiol, Shanghai, Peoples R China
5.Tongji Univ, Dept Pulm Circulat, Shanghai Pulm Hosp, Sch Med, Shanghai 200092, Peoples R China
6.Gen Hosp Shenyang Mil Command, Dept Congenital Heart Dis, Shenyang, Peoples R China
7.Fudan Univ, Dept Cardiol, Zhongshan Hosp, Shanghai 200433, Peoples R China
8.Shanghai Jiao Tong Univ, Dept Cardiol, Renji Hosp, Sch Med, Shanghai 200030, Peoples R China
9.Capital Univ Med Sci, Dept Pediat, Beijing Anzhen Hosp, Beijing, Peoples R China
10.Shanghai Jiao Tong Univ, Dept Cardiol, Shanghai Chest Hosp, Sch Med, Shanghai 200030, Peoples R China
11.Zhejiang Univ, Dept Cardiol, Affiliated Hosp 2, Coll Med, Hangzhou 310003, Zhejiang, Peoples R China
12.Second Mil Med Univ, Dept Rheumatol, Changhai Hosp, Shanghai, Peoples R China
13.Univ Tasmania, Sch Human Life Sci, Hobart, Tas 7001, Australia
14.Beijing Univ, Dept Rheumatol, Hosp 1, Beijing 100871, Peoples R China
15.Beijing Fu Wai Hosp, Dept Cardiol, Beijing, Peoples R China

Recommended Citation:
Jing, Zhi-Cheng,Strange, Geoff,Zhu, Xian-Yang,et al. Efficacy, safety and tolerability of bosentan in Chinese patients with pulmonary arterial hypertension[J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION,2010,29(2):150-156.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Jing, Zhi-Cheng]'s Articles
[Strange, Geoff]'s Articles
[Zhu, Xian-Yang]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Jing, Zhi-Cheng]‘s Articles
[Strange, Geoff]‘s Articles
[Zhu, Xian-Yang]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit
所有评论 (0)
暂无评论
 
评注功能仅针对注册用户开放,请您登录
您对该条目有什么异议,请填写以下表单,管理员会尽快联系您。
内 容:
Email:  *
单位:
验证码:   刷新
您在IR的使用过程中有什么好的想法或者建议可以反馈给我们。
标 题:
 *
内 容:
Email:  *
验证码:   刷新

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace